Portfolio News

 

   
April 15, 2016
SV Life Sciences and Health Enterprise Partners Announce Formation of Jet Health
Accomplished healthcare executive Jim Glynn to lead home healthcare platform For Immediate Release Irvine, CA, April 15, 2016 – SV Life Sciences Advisers (“SVLS”) and Health Enterprise Partners (“HEP”) announced today that they have partnered with experienced healthcare services executive Jim Glynn to form Jet Health, Inc. (“Jet Health”).

Read more

Team - James Garvey
May 2014
Kalvista Pharmaceuticals - Investment
SV Life Sciences Fund IV invested in Kalvista as part of a $5.2m Series A2 extension financing round. Kalvista is a Pharmaceutical and Ophthalmology company developing Plasma Kallikrein inhibitors.   ...

Read more

Team - Kate Bingham, Graham Boulnois
March 31, 2014
Aptiv Exit
SV Life Sciences Fund IV notes that Icon acquired Aptiv from its owners, SV Life Sciences and others for $143.5m. Aptiv is a global development services company focused on enhancing clinical trial decision making and drug and device development through the design, simulation and execution of adaptive clinical trials and a novel statistical sampling approach to risk based monitoring.

Read more

Team - Kate Bingham
November 2013
Juvaris - Investment
SV Life Sciences Fund IV invested in Juvaris, developing adjuvanted vaccines for infectious diseases as part of a $300k bridge loan financing round.  ...

Read more

Team - Bruce A Peacock, Michael Ross
October 29, 2013
Delenex Therapeutics
SV Life Sciences Advisers notes that Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing.   Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All existing venture investors, HBM Ventures, Novo A/s, SV Life Sciences, BioMedinvest and Venture Incubator participated in the round.

Read more

Team - Kate Bingham, Graham Boulnois
September 24, 2013
Ophthotech- IPO
SV Life Sciences Advisers notes that Ophthotech successfully listed on NASDAQ on 25 September 2013 NEW YORK, Sep 24, 2013 (BUSINESS WIRE) -- Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Ophthotech.

Read more

Team - David Guyer, Michael Ross
September 4, 2013
Transenterix merger with SafeStitch Medical (OTCBB: SFES)
SV Life Sciences Advisers notes that TransEnterix successfully merged with SafeStitch Medical on 4 September 2013. $30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders Combined Company to be Renamed TransEnterix MIAMI & RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--September 04, 2013 SafeStitch Medical, Inc. (OTCBB: SFES) and TransEnterix, Inc.

Read more

Team - Paul LaViolette, David Milne
April 2012
AlloCure - Investment
SV Life Science Fund IV invested in Allocure, focused on developing an allogeneic mesenchymal stem cell therapy for acute kidney injury as part of a $53m series A financing round.  ...

Read more

December 2011
TRANSENTERIX CLOSES $15M IN EQUITY FINANCING
Second tranche of Series B to accelerate development and commercialization of new flexible surgical tools SV Life Sciences notes that SV Life Sciences Fund IV invested in TransEnterix, maker of flexible medical devices that are changing how minimally invasive surgeries are performed today as part of a $15m Series B financing round. RESEARCH TRIANGLE PARK, N.C. – TransEnterix Inc. has closed $15 million in venture capital financing.

Read more

Team - Paul LaViolette, David Milne
August 17, 2011
Entellus Investment
SV Life Sciences notes that SV Life Sciences Fund IV invested in Entellus, maker of a novel balloon treatment for chronic Sinusitis as part of a $35m Series E financing round.  ...

Read more

Team - David Milne
July 6, 2011
Vantia Therapeutics Investment
SV Life Sciences notes that SV Life Sciences Fund IV invested in Vantia Therapeutics, an emergine pharmaceutifcal company developing novel, small molecule drugs as part of a £4m Series B financing round.  ...

Read more

Team - Kate Bingham
May 3, 2011
Delenex Therapeutics - Investment
SV Life Sciences notes that SV Life Sciences Fund IV invested an additional amount into Delenex Therapeutics Series A now a total A round investment of CHF 30.2m ...

Read more

Team - Kate Bingham, Graham Boulnois
April 21, 2011
Suwanee biotech Halscion raises $3.5M
SV Life Sciences notes that SV Life Sciences Fund IV invested in Halscion, developing a device for the reduction in the appearance of scars resulting from acute surgical wounds as part of a $3.5m Series A financing round. A Suwanee based biotech has raised $3.5 million, according to a Securities & Exchange Commission filing. Halscion Inc. is developing a device for the reduction in the appearance of scars resulting from acute surgical wounds. The company has raised $4.

Read more

Team - James Garvey, David Milne
March 2011
Vantia Therapeutics Investment
SV Life Sciences Fund IV invested in Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs as part of a £11m Series A financing round.  ...

Read more

Team - Kate Bingham, Hamish Cameron, Michael Carter

⇧ Back to top